AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol®), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

“We look forward to sharing the new data from our ongoing Phase 1b clinical trial evaluating tivozanib in combination with paclitaxel with the breast cancer community.”

"There are limited effective treatment options for women with metastatic breast cancer, and we believe the unique safety and efficacy profile demonstrated by tivozanib may make tivozanib well suited for use in combination with other anti-cancer agents to treat this disease," said William Slichenmyer, M.D., Sc.M., chief medical officer at AVEO. "We look forward to sharing the new data from our ongoing Phase 1b clinical trial evaluating tivozanib in combination with paclitaxel with the breast cancer community."

The details for the AVEO poster presentation at SABCS are as follows:

Date & Time: Friday, December 10, 2010 from 7:00-9:00 a.m. (CST)
Session: Poster Session 2
Location: Exhibit Halls A-B
Poster Title: Combination of Tivozanib, an Oral Inhibitor of VEGFR, with Weekly Paclitaxel for Metastatic Breast Cancer: Preliminary Results of an Ongoing Phase 1 Study
Abstract Number: P2-16-10
Presenter: E.L. Mayer

Source:

AVEO Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What is the difference in risk of early prostate cancer death between men at higher vs lower genetic risk?